Apr 2012

Home >> Clinical Trials News Archive >> 2012 >> Apr 2012
Now we’re sixty-four. In the song by the Beatles, “64” is seen as an age when health issues could impact significantly on the quality of life. The Jewish State, however, has reached that milestone by announcing yet another series of medical successes that aims to keep us all growing older gracefully.
New CenterWatch study shows investigative sites see revenue, clinical trial volume growth amid signs of recovery. Results of the study reveal sites are rebounding, with growth in both headcount and revenue during the past year.
New Israel-Korean investment fund to boost med-tech research. Together with several Israeli and foreign investment firms, the fund was launched with initial commitments of NIS 125 million (~ $34 million).
FDA Expands Investigator Disqualification To All Products. The FDA issued a final regulation April 30 that expands the scope of clinical investigator disqualification to any FDA-regulated product. The agency largely adopted the rule that was proposed last year.
FDA has issued the guidance, “Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c)."  This guidance is intended to help sponsors, investigators and Institutional Review Boards better understand the new informed consent requirement set forth in 21 CFR 50.25(c).
150 people attended the annual conference of Ctrials, the Israeli Association for the Advancement of the Biomedical Research Community, Held on March 26 2012.
The ILSI-Biomed 2012 Conference will be held May 21-23, 2012 in Tel-Aviv. This is the leading international conference covering the fast-growing field of innovation in the biomedical, health care and life sciences industries, where industry and academia join hands to learn about the latest and future developments, explore opportunities for new business ventures, meet up with old colleagues and make new contacts.